|Bid||114.02 x 1100|
|Ask||114.10 x 800|
|Day's range||113.99 - 114.97|
|52-week range||100.39 - 149.28|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||82.80|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||0.96 (0.83%)|
|Ex-dividend date||24 Jun 2022|
|1y target est||127.00|
Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.
Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.